TUHURA BIOSCIENCES INC
HURANASDAQ🏆 #3937 by market capEarnings Nov 12US Equity
$2.05▼ $0.01 (−0.49%)
Market closed · at closeTrack HURA
Get earnings, price moves & breaking news on Telegram
24h▼ 0.5%
7d▼ 1.4%
14d▲ 1.5%
30d▼ 3.8%
ytd▲ 174.0%
1y▼ 17.3%
🏦Market Cap
$131M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair
Trading Snapshot
- Day Range
- $2.04 – $2.08
- 52-Week Range
- $0.41 – $3.43
- Volume
- $2.35B
- Avg Volume
- $3.04B
- Shares Outstanding
- 63.7M
- Next Earnings
- Nov 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $4M
- P/E Ratio
- -3.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +13.2%
Why Investors Own HURA
- ✓High-growth profile — revenue up +21.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TUHURA BIOSCIENCES INC
HURAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$32M▲ +80.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$28M▲ +87.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.9M▲ +13.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▼ −$10M YoY
StockOtter · stockotter.spaceAbout TUHURA BIOSCIENCES INC
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
CNBC·2h ago
TUHURA BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift HURA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
TUHURA BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.